Edwards Lifesciences Corporation (NYSE:EW) Receives $97.09 Consensus Price Target from Analysts

Edwards Lifesciences Corporation (NYSE:EW) has been assigned an average recommendation of “Moderate Buy” from the twenty-five ratings firms that are currently covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $98.9545.

A number of equities research analysts recently weighed in on the stock. Truist Financial upped their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a report on Thursday. Evercore reissued an “outperform” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a report on Monday, July 6th. Mizuho increased their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. Wall Street Zen downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Finally, Citigroup raised their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, July 8th.

Edwards Lifesciences Stock Performance

NYSE EW opened at $85.72 on Monday. The company has a market cap of $49.36 billion, a P/E ratio of 45.60, a PEG ratio of 2.15 and a beta of 0.86. The company has a fifty day simple moving average of $87.34 and a 200 day simple moving average of $83.92. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 12-month low of $72.30 and a 12-month high of $96.29.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same period last year, the firm earned $0.64 earnings per share. The business’s quarterly revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Sell-side analysts predict that Edwards Lifesciences will post 3 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction on Friday, July 10th. The shares were sold at an average price of $91.70, for a total value of $56,762.30. Following the completion of the sale, the vice president owned 40,034 shares in the company, valued at $3,671,117.80. This represents a 1.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the sale, the vice president owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. This represents a 19.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 45,577 shares of company stock valued at $3,855,527. 0.31% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EW. Norges Bank bought a new position in Edwards Lifesciences in the 4th quarter valued at $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Edwards Lifesciences by 278.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after purchasing an additional 4,108,270 shares during the period. Viking Global Investors LP bought a new stake in shares of Edwards Lifesciences during the 3rd quarter worth $238,688,000. Marshall Wace LLP boosted its holdings in shares of Edwards Lifesciences by 66.1% in the 4th quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock worth $505,160,000 after buying an additional 2,359,128 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Edwards Lifesciences by 132.4% in the 1st quarter. Bank of America Corp DE now owns 3,883,419 shares of the medical research company’s stock worth $310,984,000 after buying an additional 2,212,208 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.